Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05220410

Organisation Name: Sheppard Pratt Health System

Overal Status: Recruiting

Start Date: February 4, 2022

Last Update: February 8, 2022

Lead Sponsor: Sheppard Pratt Health System

Brief Summary: This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation

Conditions:
  • Treatment Resistant Depression
  • Suicidal Ideation


Total execution time in seconds: 0.21758913993835